Petros Pharmaceuticals, Inc. 10-Q — AI Bull & Bear Analysis

The Q1 2026 filing reveals a company at a critical inflection point, having traded its legacy revenue streams for a high-risk, high-reward technology pivot. While the reduction in operating expenses and the strategic alignment with FDA's ACNU rules provide a theoretical path to growth, the immediate financial pressures are undeniable. The company is effectively operating as a venture-stage startup but with the baggage of a distressed public entity, including a delisted stock and a complex web of convertible securities. Ultimately, the investment thesis rests on whether management can secure a strategic partnership or a capital infusion before the remaining cash is exhausted. The massive warrant overhang means that while the upside is asymmetric, the probability of total loss for common shareholders remains high due to the imminent need for dilutive financing. The market must now weigh the potential of the Rx-to-OTC platform against the very real possibility of a liquidity-driven collapse.